Dermata Therapeutics (DRMA) closed at $0.76 on November 6, 2026, up 0.3% from the previous close, on volume of 59,272 shares (30-day average 5,872,727).
Data as of November 6, 2026.
Dermata Therapeutics Highlights Media Recognition of Tome Skincare Following Commercial Launch
ACCESS Newswire (Thu, 5-Nov 8:30 AM ET)
ACCESS Newswire (Thu, 29-Oct 4:10 PM ET)
DRMA jumps as Tome cosmetic study reports 71% seeing overall skin improvement after one treatment
Market Chameleon (Thu, 15-Oct 6:25 AM ET)
ACCESS Newswire (Thu, 15-Oct 8:05 AM ET)
Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
ACCESS Newswire (Tue, 25-Aug 8:30 AM ET)
Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
ACCESS Newswire (Fri, 21-Aug 8:30 AM ET)
ACCESS Newswire (Mon, 17-Aug 8:30 AM ET)
Dermata Sets Sights on August Launch of Tome™ as Strategic Pivot Drives Commercial Focus
Market Chameleon (Wed, 12-Aug 6:30 AM ET)
ACCESS Newswire (Tue, 11-Aug 4:10 PM ET)
Market Chameleon (Wed, 24-Dec 3:33 AM ET)
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
Dermata Therapeutics trades on the NASDAQ stock market under the symbol DRMA.
As of November 6, 2026, DRMA stock price was flat at $0.76 with 59,272 million shares trading.
DRMA has a beta of 1.73, meaning it tends to be more sensitive to market movements. DRMA has a correlation of 0.06 to the broad based SPY ETF.
DRMA has a market cap of $3.79 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, DRMA traded as high as $14.63 and as low as $.57.
The top ETF exchange traded funds that DRMA belongs to (by Net Assets): VXF.
DRMA has underperformed the market in the last year with a return of -74.1%, while the SPY ETF gained +10.8%. In the last 3 month period, DRMA fell short of the market, returning -31.2%, while SPY returned -4.1%. However, in the most recent 2 weeks DRMA has outperformed the stock market by returning -2.2%, while SPY returned -3.2%.
DRMA support price is $.68 and resistance is $.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DRMA shares will trade within this expected range on the day.
